Daniela Taranu

Dr. Daniela Taranu

Neurology, University Hospital Ulm, Ulm, Baden-Württemberg, Germany
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
DTDaniela Taranu
Daniela Taranu
Hayrettin TumaniHayrettin Tumani
Hayrettin Tumani
JHJill Holbrook
Jill Holbrook
VTVisal Tumani
Visal Tumani
IUIngo Uttner
Ingo Uttner
PFPatrick Fissler
Patrick Fissler
Tracking cognition in patients with multiple sclerosis (MS) is important for detection of disease progression but it is often not performed in routine settings due to time constraints. This exploratory cohort study aims to develop a very brief repeatable tracking tool with comparable test quality criteria to the current gold standard, the Brief International Cognitive Assessment for MS (BICAMS). The study included 88 participants (22 healthy controls, 66 MS patients) who were examined at baseline and at one-year follow-up. As a validity criterion for the six administered cognitive tests, we assessed the difference between MS patients and HC, and the correlation with MS-related disability. Combining the two tests with the highest validity—the Controlled Oral Word Association Test and Symbol Digit Modalities Test—yielded an administration time of 5 min. Comparing this new TRACK-MS test battery with the 15 min BICAMS indicated that TRACK-MS showed larger differences between MS patients and healthy controls, a higher correlation with MS-related disability, smaller practice effects, and a good test–retest reliability. We provide evidence that TRACK-MS, although faster to administer, showed at least comparable quality criteria as the BICAMS. As the study was exploratory, replication of these results is necessary.

14 May 2025 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
DTDaniela Taranu
Daniela Taranu
Luisa Theresa BalzLuisa Theresa Balz
Luisa Theresa Balz
JHJill Holbrook
Jill Holbrook
VTVisal Tumani
Visal Tumani
HSHerbert Schreiber
Herbert Schreiber
IUIngo Uttner
Ingo Uttner
Background: Multiple sclerosis (MS) subtypes—relapsing–remitting (RRMS), secondary-progressive (SPMS), and primary-progressive (PPMS) – have been associated with distinct cognitive impairment profiles, with progressive subtypes, in contrast to RRMS, showing additional deficits in more widespread domains. Research has largely focused on RRMS, leaving SPMS and PPMS underexplored due to their lower prevalence and limited therapeutic targeting. Data on the interplay between cognitive impairment, mood, and fatigue over time are also scarce. This study examined cognition, fatigue, and psychopathology over a period of one year to identify subtype-specific impairments and progression trajectories. Methods: Sixty-six MS patients (22 each with RRMS, SPMS, and PPMS) and 22 healthy controls (HC) were assessed using neuropsychological tests for attention, memory, processing speed, working memory, fluency and visuospatial functions. Patient-reported outcomes for depression, anxiety, and fatigue were also collected. Analyses included correlations, within-group comparisons (paired t-tests), and between-group comparisons (ANOVAs/ANCOVAs). Results: Progressive MS subtypes exhibited more severe cognitive impairments, fatigue, and mood disturbances than RRMS. Over one year, treated RRMS patients improved in various cognitive domains, while PPMS patients showed gains only in visuospatial abilities. On the other hand, SPMS patients exhibited no significant changes, suggesting more pronounced cognitive deficits. Conclusions: Cognitive impairments differed significantly across MS subtypes. While RRMS patients improved over one year and PPMS patients showed selective gains in one domain, SPMS showed no significant changes, indicating reduced cognitive reserve. These between-group differences suggest different cognitive trajectories. The findings underscore the need for tailored, holistic interventions for different MS subtypes.

3 May 2024 in European Journal of Neurology
Verified
Journal Article
Open access
IVIoannis Vardakas
Ioannis Vardakas
JDJohannes Dorst
Johannes Dorst
AHAndré Huss
André Huss
BMBenjamin Mayer
Benjamin Mayer
TFTanja Fangerau
Tanja Fangerau
MSMakbule Senel
Makbule Senel
Background and purpose: The predictive value of serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) for apheresis outcome in steroid‐refractory multiple sclerosis (MS) relapse has not yet been evaluated.Methods: We used pre‐ and postapheresis serum samples from 38 participants of the IAPEMS trial (clinicaltrials.gov: NCT02671682), which investigated the use of immunoadsorption versus plasma exchange for the treatment of steroid‐refractory MS attacks. Response to apheresis was classified based on improvement on (i) the Expanded Disability Status Scale (EDSS), (ii) the affected functional system scores (FSS) of the EDSS, or (iii) the visual acuity for patients with optic neuritis, 4 weeks postapheresis. sNFL and sGFAP were measured by single molecule arrays.Results: Preprocedural sGFAP levels could discriminate between responders and nonresponders, determined by FSS improvement (p = 0.017). In multivariate logistic regression analysis, younger age (odds ratio [OR] = 0.781, 95% confidence interval [CI] = 0.635–0.962, p = 0.020) and lower sGFAP levels (OR = 0.948, 95% CI = 0.903–0.995, p = 0.031) could predict response to apheresis in the overall cohort. We could observe a trend towards a favourable apheresis outcome with higher sNfL levels (OR = 1.413, 95% CI = 0.965–2.069, p = 0.076). Analysis of the sNfL‐to‐sGFAP ratio showed an OR of 1.924 (95% CI = 1.073–3.451, p = 0.028) for predicting apheresis response. The ratio showed a better predictive value than the individual parameters. Neither biomarker was affected by the number of steroid cycles preapheresis.Conclusions: Lower sGFAP levels, a higher sNfL‐to‐sGFAP ratio, and younger age are associated with a favourable apheresis outcome.

1 May 2020 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
SMSebastian Michels
Sebastian Michels
EZEugen Zizer
Eugen Zizer
TBThomas FE Barth
Thomas FE Barth
AWAnette Wassner
Anette Wassner
TFTanja Fangerau
Tanja Fangerau
MSMakbule Senel
Makbule Senel

15 April 2025 in Multiple Sclerosis Journal – Experimental, Translational and Clinical
Verified
Journal Article
Open access
IVIoannis Vardakas
Ioannis Vardakas
JDJohannes Dorst
Johannes Dorst
AHAndré Huss
André Huss
BMBenjamin Mayer
Benjamin Mayer
PEPia Eichele
Pia Eichele
MSMakbule Senel
Makbule Senel
Background: Evidence on neurochemical mechanisms underlying response to apheresis in steroid-refractory Multiple Sclerosis (MS) attacks is limited. Objective: To examine the effect of immunoadsorption (IA) versus plasma exchange (PLEX) on serum immunological parameters [IgG, IgA, IgM, kappa- and lambda-immunoglobulin free light chains (κ-FLC, λ-FLC), CXCL13, CXCL12] and the predictive value of these parameters on response to apheresis. Methods: Pre- and postprocedural serum samples of 38 participants (IA: n = 19, PLEX: n = 19) from the IAPEMS trial (NCT02671682), conducted in our tertiary centre, were examined. Results: Serum immunoglobulins were strongly reduced after both procedures (IgG: IA median −96.04%; PLEX median −85.98%). κ-FLC levels were reduced after PLEX (median −34.74%), not affected by IA. Both procedures caused a decrease in λ-FLC levels. CXCL13 slightly increased after PLEX (median +24.16%), conversely decreased after IA (median −21.92%). CXCL12 levels were reduced after IA (median −45.69%), but not significantly altered after PLEX. None of the serum parameters evaluated showed predictive value for apheresis response. Conclusion: IA and PLEX have a differential effect on serum immunological parameters. IA appears to reduce B-cell derived inflammation more effectively. This finding requires further evaluation and comparative analysis with clinical outcomes, especially in the context of the efficacy of B-cell therapies in treating MS.

4 August 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Luisa Theresa BalzLuisa Theresa Balz
Luisa Theresa Balz
IUIngo Uttner
Ingo Uttner
DTDaniela Taranu
Daniela Taranu
DEDeborah Katharina Erhart
Deborah Katharina Erhart
TFTanja Fangerau
Tanja Fangerau
Hayrettin TumaniHayrettin Tumani
Hayrettin Tumani
Background/Objectives: Cognitive impairment is one of the most common and debilitating clinical features of Multiple Sclerosis (MS). Neuropsychological assessment, however, is time-consuming and requires personal resources, so, due to limited resources in daily clinical practice, information on cognitive profiles is often lacking, despite its high prognostic relevance. Time-saving and effective tools are required to bridge this gap. This study evaluates the sensitivity and specificity of a revised version of TRACK-MS (TRACK-MS-R), a recently published screening tool to identify cognitive impairment in MS in a fast and reliable way, offering a balance between efficiency and diagnostic yield for the individual patient. Methods: In this prospective cross-sectional study, 102 MS patients and 94 age-, sex-, and education-matched healthy controls (HC) completed an extensive neuropsychological assessment, including TRACK-MS-R, to test for cognitive processing speed (Symbol Digit Modalities Test, SDMT) and verbal fluency (Regensburger Word Fluency Test, RWT). Sensitivity of TRACK-MS-R was assessed by using the BICAMS-M battery as a reference, and specificity was determined by comparing MS patients to HC. Results: TRACK-MS-R demonstrated high sensitivity (97.44%) when compared to the gold standard as represented by BICAMS-M for early and accurately detecting cognitive impairment in MS patients. Additionally, as a potential cognitive marker, TRACK-MS-R showed a specificity of 82.98% in distinguishing MS patients from healthy controls. Conclusions: TRACK-MS-R proves to be a highly sensitive and time-efficient screening tool for detecting cognitive impairment in patients with MS, while demonstrating good specificity compared to HC. Whereas high sensitivity is a prerequisite for a valid screening tool, its relatively modest specificity compared to BICAMS-M (62.9%) calls for caution in interpreting standalone results but instead indicates more extensive neuropsychological testing. Its briefness and diagnostic accuracy support its implementation in routine clinical practice, particularly in time-constrained settings.